Volume 29, Number 4—April 2023
Research
Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5–11 Years of Age, Israel
Aharona Glatman-Freedman
, Yael Hershkovitz, Rita Dichtiar, Alina Rosenberg, Lital Keinan-Boker, and Michal Bromberg
, Yael Hershkovitz, Rita Dichtiar, Alina Rosenberg, Lital Keinan-Boker, and Michal Bromberg
Table 1
Characteristics of SARS-CoV-2 cases included in study of effectiveness of BNT162b2 vaccine against Omicron variant infection in children 5–11 years of age, January 20–February 15, 2022, Israel
| Variable | Cases, no. (%), n = 78,541 |
|---|---|
| Age, y | |
| 5 | 9,783 (12.5) |
| 6 | 11,310 (14.4) |
| 7 | 11,529 (14.7) |
| 8 | 11,599 (14.8) |
| 9 | 11,468 (14.6) |
| 10 | 11,562 (14.7) |
| 11 |
11,290 (14.4) |
| Sex | |
| F | 39,175 (49.9) |
| M |
39,366 (50.1) |
| Population group | |
| Ultra-Orthodox Jews | 2,194 (2.8) |
| General* | 54,700 (69.6) |
| Arabs |
21,647 (27.6) |
| Socioeconomic status | |
| Low | 26,048 (33.2) |
| Medium | 36,515 (46.5) |
| High | 15,978 (20.3) |
*Includes non–ultra-Orthodox Jews and non-Arab minorities.
Page created: February 08, 2023
Page updated: March 20, 2023
Page reviewed: March 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.